See more : Poxel S.A. (0RA2.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cryptoblox Technologies Inc. (CRYBF) Income Statement Analysis – Financial Results
- Ion Exchange (India) Limited (IONEXCHANG.NS) Income Statement Analysis – Financial Results
- Sega Sammy Holdings Inc. (6460.T) Income Statement Analysis – Financial Results
- Durango Resources Inc. (DGO.V) Income Statement Analysis – Financial Results
- PANORAMA STUDIOS INTERNATIONAL (PANORAMA.BO) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Cardio Diagnostics Holdings, Inc to Attend 22nd Annual AHOU Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is participating and exhibiting at the 22nd Annual Association of Home Office Underwriters (AHOU) Conference, a premier event for the life insurance underwriting industry. The conference will take place...
Cardio Diagnostics Holdings, Inc Announces Strategic Engagement with Lifespan.io to Drive Longevity & Heart Disease Research and Education
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced a strategic engagement with Lifespan.io, a leading nonprofit advocacy foundation and online platform focusing on the extension of healthy human lifespan through research and...
Cardio Diagnostics Holdings, Inc Sponsors Becker’s Hospital Review 13th Annual Meeting
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual Meeting. The conference is taking place next week, April 3-6, 2023, at the Hyatt Regency Hotel in Chicago. As part of Cardio...
Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (the “Company”) (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that it has entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by...
Cardio Diagnostics Holdings, Inc Welcomes Dr. Damon Broyles, MD, as Strategic Advisor for Precision Cardiovascular Medicine Strategy
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced Dr. Damon Broyles, MD, the VP of Clinical Innovation at Mercy Technology Services (MTS), the technical support arm of Mercy Healthcare, has joined Cardio...
Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4,...
Penny Stocks: The Importance of Liquidity and Volume
Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cardio Diagnostics Holdings Inc Launches Revolutionary Blood Test for Early Detection of Coronary Heart Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. PrecisionCHD is the second clinical test built...
Cardio Diagnostics Holdings Inc to Debut PrecisionCHD™ at the American College of Cardiology’s 72nd Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that its newest coronary heart disease test, PrecisionCHD™, will be presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), taking place...
Penny Stocks Vs. Blue Chips, Which Should You Trade?
Are penny stocks better than blue chips? Here's why The post Penny Stocks Vs.
Source: https://incomestatements.info
Category: Stock Reports